1. SARS-CoV-2 Viremia is Associated with COVID-19 Severity and Predicts Clinical Outcomes
- Author
-
Jacobs, Jana L., Bain, William, Naqvi, Asma, Staines, Brittany, Castanha, Priscila M. S., Yang, Haopu, Boltz, Valerie F., Barratt-Boyes, Simon, Marques, Ernesto T. A., Mitchell, Stephanie L., Methé, Barbara, Olonisakin, Tolani F., Haidar, Ghady, Burke, Thomas W., Petzold, Elizabeth, Denny, Thomas, Woods, Chris W., McVerry, Bryan J., Lee, Janet S., Watkins, Simon C., St. Croix, Claudette M., Morris, Alison, Kearney, Mary F., Ladinsky, Mark S., Bjorkman, Pamela J., Kitsios, Georgios, and Mellors, John W.
- Subjects
viruses ,biochemical phenomena, metabolism, and nutrition - Abstract
Background: SARS-CoV-2 viral RNA (vRNA) is detected in the bloodstream of some patients with COVID-19 (“RNAemia”) but it is not clear whether this RNAemia reflects viremia (i.e., virus particles) and how RNAemia/viremia is related to host immune responses and outcomes. Methods: SARS-CoV-2 vRNA was quantified by ultra-sensitive RT-PCR in plasma samples (0.5-1.0 ml) from observational cohorts of 51 COVID-19 patients including 9 outpatients, 19 hospitalized (non-ICU), and 23 ICU patients, and vRNA levels compared with cross-sectional indices of COVID-19 severity and prospective clinical outcomes. We used multiple imaging methods to visualize virions in pelleted plasma. Results: SARS-CoV-2 vRNA was detected in plasma of 100%, 52.6% and 11.1% of ICU, non-ICU, and outpatients respectively. Virions were detected in plasma pellets by electron tomography and immunostaining. Plasma vRNA levels were significantly higher in ICU > non-ICU > outpatients (p6,000 copies/ml was strongly associated with mortality (HR: 10.7). Levels of vRNA were significantly associated with several inflammatory biomarkers (p
- Published
- 2021